Your browser doesn't support javascript.
loading
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Penter, Livius; Zhang, Yi; Savell, Alexandra; Huang, Teddy; Cieri, Nicoletta; Thrash, Emily M; Kim-Schulze, Seunghee; Jhaveri, Aashna; Fu, Jingxin; Ranasinghe, Srinika; Li, Shuqiang; Zhang, Wandi; Hathaway, Emma S; Nazzaro, Matthew; Kim, Haesook T; Chen, Helen; Thurin, Magdalena; Rodig, Scott J; Severgnini, Mariano; Cibulskis, Carrie; Gabriel, Stacey; Livak, Kenneth J; Cutler, Corey; Antin, Joseph H; Nikiforow, Sarah; Koreth, John; Ho, Vincent T; Armand, Philippe; Ritz, Jerome; Streicher, Howard; Neuberg, Donna; Hodi, F Stephen; Gnjatic, Sacha; Soiffer, Robert J; Liu, X Shirley; Davids, Matthew S; Bachireddy, Pavan; Wu, Catherine J.
Afiliación
  • Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Zhang Y; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Savell A; Harvard Medical School, Boston, MA.
  • Huang T; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Cieri N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Thrash EM; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Kim-Schulze S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Jhaveri A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Fu J; Translational Immunogenomics Laboratory and.
  • Ranasinghe S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Li S; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Zhang W; Harvard Medical School, Boston, MA.
  • Hathaway ES; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Nazzaro M; Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai, New York, NY.
  • Kim HT; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Chen H; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Thurin M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Rodig SJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Severgnini M; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Cibulskis C; Translational Immunogenomics Laboratory and.
  • Gabriel S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Livak KJ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Cutler C; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Antin JH; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Nikiforow S; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and.
  • Koreth J; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and.
  • Ho VT; Department of Pathology and.
  • Armand P; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Ritz J; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Streicher H; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Neuberg D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Hodi FS; Translational Immunogenomics Laboratory and.
  • Gnjatic S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Soiffer RJ; Harvard Medical School, Boston, MA.
  • Liu XS; Department of Medicine, Brigham and Women's Hospital, Boston, MA.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Bachireddy P; Harvard Medical School, Boston, MA.
  • Wu CJ; Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Blood ; 137(23): 3212-3217, 2021 06 10.
Article en En | MEDLINE | ID: mdl-33720354
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulación Leucémica de la Expresión Génica / Trasplante de Células Madre Hematopoyéticas / Linfocitos T CD8-positivos / Antígeno CTLA-4 / Ipilimumab / Proteínas de Neoplasias Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulación Leucémica de la Expresión Génica / Trasplante de Células Madre Hematopoyéticas / Linfocitos T CD8-positivos / Antígeno CTLA-4 / Ipilimumab / Proteínas de Neoplasias Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: Marruecos